The overall goal of this program is to emphasize scientific paradigms focused on treatment of local / regional disease, with the ultimate objective of achieving long term control of such tumors, while maintaining normal tissue integrity. The paradigm is being approached two ways: 1) Therapeutic approaches to increase tumor response or reduce normal tissue damage, and 2) Development of diagnostic methods to predict outcome or guide therapeutic decisions before or during treatment. The fact that radiation therapy is used as part of therapy for nearly all forms of cancer means that the clinical collaborations are varied and multidisciplinary. Members cross many disciplines, including molecular biology and signal transduction, transgenic model development, physiology, angiogenesis, hyperthermia, engineering, drug carrier development, imaging, radiation biology and clinical trial development and conduct. This program is centered in a clinical department, which helps to focus efforts toward translational studies. The program has incorporated MR and CT/PET imaging capabilities into research activities with the acquisition of this hardware for research purposes. Several protocols now include opportunities for direct acquisition of tissues and / or plasma samples that can be used for correlative science investigations. Significant improvement has been made in the basic science component of the program, with successful recruitment of clinical faculty with interests in transgenic models of human cancer and in translational studies involving breast cancer radiotherapy. The program sponsors several venues for interaction, offered on a bi-weekly to yearly basis to facilitate collaborations within and with other programs. Since the last competing renewal, members of this program have published 424 peer reviewed papers; over 90% of which have been directly related to cancer. Nearly 50% of the publications have involved inter- or intra- programmatic collaborations. The patient census has grown by 35%, from 978 treatment starts in 2004 to well over 1300 in 2007. The percentage of patients enrolled on protocols has averaged just over 6%. Accrual of minorities and women has averaged 18% and 57%, respectively. Clinical trial and grants management infrastructure has been substantially improved, which is paying dividends with respect to easing initiation of new investigator initiated trials. The Program includes 24 members from 5 basic and clinical departments. Total funding for program members is $12,819,957, of Which $8,288,024 is from peer-reviewed sources. A cancer focus is illustrated by $4,758,760 or 57.4% of funding from the NCI, the American Cancer Society or the Department of Defense.

Public Health Relevance

Approximately 50% of all cancer patients are treated with radiotherapy, and of those, a significant percentage are treated with curative intent. Given the widespread use of this modality, it is imperative that means be established to increase the likelihood that local tumor control can be achieved, while preserving the integrity of normal tissues. This common paradigm fits this program well, bit it is now being addressed with modern radiotherapy practices in the context of cutting-edge imaging and translational sciences.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
3P30CA014236-38S1
Application #
8532208
Study Section
Subcommittee G - Education (NCI)
Project Start
Project End
Budget Start
2012-01-01
Budget End
2012-12-31
Support Year
38
Fiscal Year
2012
Total Cost
$2,501
Indirect Cost
$908
Name
Duke University
Department
Type
DUNS #
044387793
City
Durham
State
NC
Country
United States
Zip Code
27705
McDonnell, Eoin; Crown, Scott B; Fox, Douglas B et al. (2016) Lipids Reprogram Metabolism to Become a Major Carbon Source for Histone Acetylation. Cell Rep 17:1463-1472
Liu, Hongliang; Gao, Fengqin; Dahlstrom, Kristina R et al. (2016) A variant at a potentially functional microRNA-binding site in BRIP1 was associated with risk of squamous cell carcinoma of the head and neck. Tumour Biol 37:8057-66
Evans, M K; Sauer, S J; Nath, S et al. (2016) X-linked inhibitor of apoptosis protein mediates tumor cell resistance to antibody-dependent cellular cytotoxicity. Cell Death Dis 7:e2073
Pollock, Julie A; Wardell, Suzanne E; Parent, Alexander A et al. (2016) Inhibiting androgen receptor nuclear entry in castration-resistant prostate cancer. Nat Chem Biol 12:795-801
He, Kevin; Li, Yanming; Zhu, Ji et al. (2016) Component-wise gradient boosting and false discovery control in survival analysis with high-dimensional covariates. Bioinformatics 32:50-7
Yuan, Hua; Liu, Hongliang; Liu, Zhensheng et al. (2016) A Novel Genetic Variant in Long Non-coding RNA Gene NEXN-AS1 is Associated with Risk of Lung Cancer. Sci Rep 6:34234
Schaal, Jeffrey L; Li, Xinghai; Mastria, Eric et al. (2016) Injectable polypeptide micelles that form radiation crosslinked hydrogels in situ for intratumoral radiotherapy. J Control Release 228:58-66
Pilaz, Louis-Jan; Lennox, Ashley L; Rouanet, Jeremy P et al. (2016) Dynamic mRNA Transport and Local Translation in Radial Glial Progenitors of the Developing Brain. Curr Biol 26:3383-3392
Matak, Pavle; Matak, Andrija; Moustafa, Sarah et al. (2016) Disrupted iron homeostasis causes dopaminergic neurodegeneration in mice. Proc Natl Acad Sci U S A 113:3428-35
Friedman, Daphne R; Sibley, Alexander B; Owzar, Kouros et al. (2016) Relationship of blood monocytes with chronic lymphocytic leukemia aggressiveness and outcomes: a multi-institutional study. Am J Hematol 91:687-91

Showing the most recent 10 out of 443 publications